Tuberculosis treatment monitoring and outcome measures: new interest and new strategies

UNITE4TB Consortium; Jan Heyckendorf; Sophia B Georghiou; Nicole Frahm; Norbert Heinrich; Irina Kontsevaya; Maja Reimann; David Holtzman; Marjorie Imperial; Daniela M Cirillo; Stephen H Gillespie; Morten Ruhwald

doi:10.1128/cmr.00227-21

Tuberculosis treatment monitoring and outcome measures: new interest and new strategies

UNITE4TB Consortium, Jan Heyckendorf, Sophia B Georghiou, Nicole Frahm, Norbert Heinrich, Irina Kontsevaya, Maja Reimann, David Holtzman, Marjorie Imperial, Daniela M Cirillo, Stephen H Gillespie, Morten Ruhwald^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

Abstract

Despite the advent of new diagnostics, drugs and regimens, tuberculosis (TB) remains a global public health threat. A significant challenge for TB control efforts has been the monitoring of TB therapy and determination of TB treatment success. Current recommendations for TB treatment monitoring rely on sputum and culture conversion, which have low sensitivity and long turnaround times, present biohazard risk, and are prone to contamination, undermining their usefulness as clinical treatment monitoring tools and for drug development. We review the pipeline of molecular technologies and assays that serve as suitable substitutes for current culture-based readouts for treatment response and outcome with the potential to change TB therapy monitoring and accelerate drug development.

Original language	English
Article number	e0022721
Number of pages	21
Journal	Clinical Microbiology Reviews
Volume	35
Issue number	3
Early online date	21 Mar 2022
DOIs	https://doi.org/10.1128/cmr.00227-21
Publication status	Published - 21 Sept 2022

Keywords

Tuberculosis
Treatment monitoring
Biomarkers
Outcome

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1128/cmr.00227-21

Unite4TB H2020: Unite4TB: Academia and industry united innovation and treatment for tuberculosis
Gillespie, S. H. (PI), Sabiiti, W. (CoI) & Sloan, D. J. (CoI)
European Commission
1/06/21 → 1/05/25
Project: Standard

Cite this

UNITE4TB Consortium, Heyckendorf, J., Georghiou, S. B., Frahm, N., Heinrich, N., Kontsevaya, I., Reimann, M., Holtzman, D., Imperial, M., Cirillo, D. M., Gillespie, S. H., & Ruhwald, M. (2022). Tuberculosis treatment monitoring and outcome measures: new interest and new strategies. Clinical Microbiology Reviews, 35(3), Article e0022721. https://doi.org/10.1128/cmr.00227-21

@article{7ffd40fc97a24c828c40151927b03f93,

title = "Tuberculosis treatment monitoring and outcome measures: new interest and new strategies",

abstract = "Despite the advent of new diagnostics, drugs and regimens, tuberculosis (TB) remains a global public health threat. A significant challenge for TB control efforts has been the monitoring of TB therapy and determination of TB treatment success. Current recommendations for TB treatment monitoring rely on sputum and culture conversion, which have low sensitivity and long turnaround times, present biohazard risk, and are prone to contamination, undermining their usefulness as clinical treatment monitoring tools and for drug development. We review the pipeline of molecular technologies and assays that serve as suitable substitutes for current culture-based readouts for treatment response and outcome with the potential to change TB therapy monitoring and accelerate drug development.",

keywords = "Tuberculosis, Treatment monitoring, Biomarkers, Outcome",

author = "{UNITE4TB Consortium} and Jan Heyckendorf and Georghiou, {Sophia B} and Nicole Frahm and Norbert Heinrich and Irina Kontsevaya and Maja Reimann and David Holtzman and Marjorie Imperial and Cirillo, {Daniela M} and Gillespie, {Stephen H} and Morten Ruhwald",

note = "Funding: The UNITE4TB project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement 101007873. The JU receives support from the European Union{\textquoteright}s Horizon 2020 research and innovation program and EFPIA, Deutsches Zentrum f{\"u}r Infektionsforschung e. V. (DZIF), and Ludwig-Maximilians-Universit{\"a}t M{\"u}nchen (LMU). EFPIA/AP contribute to 50% of funding, whereas the contribution of DZIF and the LMU University Hospital Munich has been granted by the German Federal Ministry of Education and Research.",

year = "2022",

month = sep,

day = "21",

doi = "10.1128/cmr.00227-21",

language = "English",

volume = "35",

journal = "Clinical Microbiology Reviews",

issn = "0893-8512",

publisher = "American Society for Microbiology",

number = "3",

}

TY - JOUR

T1 - Tuberculosis treatment monitoring and outcome measures

T2 - new interest and new strategies

AU - UNITE4TB Consortium

AU - Heyckendorf, Jan

AU - Georghiou, Sophia B

AU - Frahm, Nicole

AU - Heinrich, Norbert

AU - Kontsevaya, Irina

AU - Reimann, Maja

AU - Holtzman, David

AU - Imperial, Marjorie

AU - Cirillo, Daniela M

AU - Gillespie, Stephen H

AU - Ruhwald, Morten

N1 - Funding: The UNITE4TB project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement 101007873. The JU receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA, Deutsches Zentrum für Infektionsforschung e. V. (DZIF), and Ludwig-Maximilians-Universität München (LMU). EFPIA/AP contribute to 50% of funding, whereas the contribution of DZIF and the LMU University Hospital Munich has been granted by the German Federal Ministry of Education and Research.

PY - 2022/9/21

Y1 - 2022/9/21

N2 - Despite the advent of new diagnostics, drugs and regimens, tuberculosis (TB) remains a global public health threat. A significant challenge for TB control efforts has been the monitoring of TB therapy and determination of TB treatment success. Current recommendations for TB treatment monitoring rely on sputum and culture conversion, which have low sensitivity and long turnaround times, present biohazard risk, and are prone to contamination, undermining their usefulness as clinical treatment monitoring tools and for drug development. We review the pipeline of molecular technologies and assays that serve as suitable substitutes for current culture-based readouts for treatment response and outcome with the potential to change TB therapy monitoring and accelerate drug development.

AB - Despite the advent of new diagnostics, drugs and regimens, tuberculosis (TB) remains a global public health threat. A significant challenge for TB control efforts has been the monitoring of TB therapy and determination of TB treatment success. Current recommendations for TB treatment monitoring rely on sputum and culture conversion, which have low sensitivity and long turnaround times, present biohazard risk, and are prone to contamination, undermining their usefulness as clinical treatment monitoring tools and for drug development. We review the pipeline of molecular technologies and assays that serve as suitable substitutes for current culture-based readouts for treatment response and outcome with the potential to change TB therapy monitoring and accelerate drug development.

KW - Tuberculosis

KW - Treatment monitoring

KW - Biomarkers

KW - Outcome

U2 - 10.1128/cmr.00227-21

DO - 10.1128/cmr.00227-21

M3 - Review article

C2 - 35311552

SN - 0893-8512

VL - 35

JO - Clinical Microbiology Reviews

JF - Clinical Microbiology Reviews

IS - 3

M1 - e0022721

ER -

Tuberculosis treatment monitoring and outcome measures: new interest and new strategies

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Projects

Unite4TB H2020: Unite4TB: Academia and industry united innovation and treatment for tuberculosis

Cite this